Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets
Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets
DOI | Resolve DOI: https://doi.org/10.1016/j.celrep.2013.08.028 |
---|---|
Author | Search for: 1; Search for: ; Search for: 1; Search for: ; Search for: 1; Search for: 1; Search for: 1; Search for: ; Search for: ; Search for: 1; Search for: 1; Search for: 1 |
Affiliation |
|
Format | Text, Article |
Subject | antineoplastic agent; bms 536924; bosutinib; docetaxel; erlotinib; nutlin 3; protein kinase B inhibitor; rapamycin; rdea 119; tamoxifen; tanespimycin; tcs 2312; tozasertib; unclassified drug; breast cancer; cancer cell; cancer classification; cell proliferation; cell survival; copy number variation; drug sensitivity; drug targeting; exome; gene identification; gene mutation; gene sequence; genetic screening; human cell; mutation; signal transduction; tumor gene |
Abstract | |
Publication date | 2013 |
In | |
Language | English |
Peer reviewed | Yes |
NPARC number | 21270576 |
Export citation | Export as RIS |
Report a correction | Report a correction (opens in a new tab) |
Record identifier | 6f7d4adc-37d5-4bf8-9e45-130377e20eb8 |
Record created | 2014-02-17 |
Record modified | 2020-04-22 |
- Date modified: